UNIT 14.12 Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non-Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In Situ: Applications in Evaluating Novel Therapeutic Agents
Published Online: 1 JUN 2009
Copyright © 2009 by John Wiley & Sons, Inc.
Lab Protocol Title
Current Protocols in Pharmacology
How to Cite
Connolly, D. C. and Hensley, H. H. 2009. Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non-Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In Situ: Applications in Evaluating Novel Therapeutic Agents. Current Protocols in Pharmacology. 45:14.12:14.12.1–14.12.26.
- Published Online: 1 JUN 2009
- Published Print: JUN 2009
Epithelial ovarian cancer (EOC) is the most commonly fatal gynecologic malignancy in developed countries. Most EOC patients are diagnosed at an advanced stage when disease has spread beyond the ovary. While many patients initially respond to surgery and chemotherapy, the long-term prognosis is generally unfavorable, with recurrence and development of drug-resistant disease. There is a critical need to identify new therapeutic agents that prolong disease-free intervals and effectively manage recurrent disease. Murine models of ovarian carcinoma are excellent models to study tumor biology in the search for new treatments for EOC. Described in this unit are methods for establishing xenograft or allograft models of EOC using ovarian carcinoma cell lines, in vivo imaging strategies for detection and quantification of EOC in transgenic and in xenograft/allograft models, and procedures for necropsy and pathological evaluation of experimental animals. Curr. Protoc. Pharmacol. 45:14.12.1-14.12.26. © 2009 by John Wiley & Sons, Inc.
- epithelial ovarian cancer (EOC);
- transgenic mice;
- in vivo imaging;
- magnetic resonance imaging;
- bioluminescent imaging